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ABSTRACT  
Proprotein convertase subtilisin/kexin 9 (PCSK9), a protein regulating the number of cell-surface LDL 
receptors (LDLR), circulates partially associated to plasma lipoproteins. How this interaction alters 
PCSK9 plasma levels is still unclear. In the present study, we took advantage of the availability of a large 
cohort of carriers of genetic HDL disorders to evaluate how HDL defects affect plasma PCSK9 levels and 
its distribution among lipoproteins. Plasma PCSK9 concentrations were determined by ELISA in carriers 
of mutations in LCAT, ABCA1, or APOAI genes, and lipoprotein distribution was analyzed by FPLC. 
Carriers of one or two mutations in the LCAT gene show plasma PCSK9 levels comparable to that of 
unaffected family controls (homozygotes, 159.4 ng/mL (124.9;243.3); heterozygotes, 180.3 ng/mL 
(127.6;251.5) and controls, 190.4 ng/mL (146.7;264.4); P for trend =0.33). Measurement of PCSK9 in 
plasma of subjects carrying mutations in ABCA1 or APOAI genes confirmed normal values. When 
fractionated by FPLC, PCSK9 peaked in a region between LDL and HDL in control subjects. In carriers 
of all HDL defects, lipoprotein profile shows a strong reduction of HDL, but the distribution of PCSK9 
was superimposable to that of controls. In conclusion, the present study demonstrates that in genetically 
determined low HDL states plasma PCSK9 concentrations and lipoprotein distribution are preserved, thus 
suggesting that HDL may not be involved in PCSK9 transport in plasma. 
 
Keywords: proprotein convertase subtilisin/kexin 9, high-density lipoproteins, genetic HDL disorders, 
lecithin:cholesterol acyltransferase. 
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1. Introduction 
Proprotein convertase subtilisin/kexin 9 (PCSK9) is predominantly expressed in liver, intestine, 
kidney, and aortic vessels [1, 2]. PCSK9 regulates, by a post-translational mechanism, the number of cell-
surface LDL receptors (LDLR) in the liver and in other tissues, ie, lung, adipose tissue, and kidney [3]. 
The PCSK9 gene encodes a 692-amino acid glycoprotein constituted by a signal peptide, a prodomain, a 
subtilisin-like catalytic domain, and a variable C-terminal domain [4]. PCSK9 contains a catalytic triad 
(Asp186, His226, and Ser386), in the catalytic domain, essential for its processing occurring in the secretory 
pathway. The autocatalytic cleavage generates a stable PCSK9 heterodimer composed of a 10-kDa 
prodomain fragment and a mature 64-kDa fragment containing the catalytic and C-terminal domains. The 
interaction of the prodomain with the catalytic domain occupies the active site inhibiting further 
enzymatic activity by PCSK9 that is found in an inactive 64-kDa form in plasma. A second circulating 
cleaved form of PCSK9 can be detected in human plasma as a result of furin-mediated processing [5]. 
A significant proportion of plasma PCSK9 (20-40%) circulates bound to lipoproteins. The observation 
that more than half of PCSK9 is removed from plasma together with LDL by LDL-apheresis [6] confirms 
a binding between LDL and PCSK9. The cleaved form of PCSK9 has also been found associated to LDL 
and to be cleared after apheresis [6, 7]. The association of PCSK9 with LDL particles lowers the ability of 
PCSK9 to bind to cell surface LDLRs thereby blunting PCSK9-mediated LDLR degradation [8]. In 
addition, PCSK9 also binds to Lp(a) [9], an effect that could partially explain the reduction of plasma 
Lp(a) levels observed in hypercholesterolemic patients treated with monoclonal antibodies against 
PCSK9 [10, 11], for which the molecular mechanism is still unknown, although pathways beyond the 
LDLR appears to be involved [12]. More controversial is the binding of PCSK9 to HDL [13]. Although 
Kosenko et al showed that PCSK9 binds to L L but not to HDL [8], the incubation of human PCSK9 
with mouse serum clearly demonstrated the association of PCSK9 with LDL and HDL, but not with 
VLDL [14]. Fast Protein Liquid Chromatography (FPLC) analysis of PCSK9 distribution within plasma 
lipoproteins in transgenic mice overexpressing human PCSK9 showed that the majority of PCSK9 
overlapped with the distribution of purified human PCSK9, thus suggesting that PCSK9 circulates in 
plasma mostly as free form [15]. On the contrary, a small fraction of PCSK9 was present in a large 
complex that co-eluted with LDL fractions [15]. Overall, approximately 20-40% of PCSK9 associates to 
LDL, while the remaining part is found in the apoB free fractions [8, 15, 16]. 
In the present study we took advantage from the availability of a relatively large cohort of carriers of 
genetic HDL defects, carrying mutations in the APOAI, LCAT, and ABCA1 genes to investigate the 
impact of HDL deficiency on plasma PCSK9 concentration as well as distribution among different 
lipoprotein particles.  
 
2. Materials and Methods 
2.1. Subjects 
Seventy-nine carriers of LCAT gene mutations and 35 non-affected family controls, all belonging to 
the Italian LCAT deficient families [17-20], volunteered for the study. The carriers’ group was comprised 
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of 10 homozygotes and 9 compound heterozygotes, defined homozygotes throughout the paper, and 60 
heterozygotes. In addition, 2 carriers of two mutations in the ABCA1 gene, 2 carriers of one mutation in 
the ABCA1 gene, 2 carriers of two mutations in the APOAI gene and 4 carriers of one mutation in the 
APOAI gene were included in the study [17-23]. A detailed complete overview of the LCAT, ABCA1, 
and ApoA-I mutations can be found in the Supplemental Table I. All subjects were fully informed of the 
modalities and end points of the study and signed an informed consent, and the procedures were approved 
by the Institutional Review Board. 
Fasting blood was collected after an overnight fast; plasma was prepared by low speed centrifugation 
and stored in aliquots at -80°C until utilization. 
 
2.2. Biochemical analyses 
Plasma lipids (total and HDL cholesterol, unesterified cholesterol, triglycerides, and phospholipids) 
were measured by certified enzymatic techniques on a Roche c311 autoanalyzer. Apolipoprotein and 
Lp(a) levels were measured by immunoturbidimetry on a Roche c311 autoanalyzer. In addition, LDL and 
non-HDL cholesterol were calculated by the Friedewald’s equation and as the difference between total 
and HDL cholesterol, respectively.  
Plasma LCAT concentration was measured by an immunoenzymatic assay [19], and LCAT activity 
was measured as the esterification of cholesterol incorporated into an exogenous standardized substrate 
(reconstituted HDL) as previously described [19].  
Plasma PCSK9 concentrations were measured by a commercial ELISA kit (R&D Systems, MN) able 
to recognize free and LDLR-bound PCSK9 [24]. Plasma samples were diluted 1:20 and incubated onto a 
microplate pre-coated with a monoclonal antibody specific for human PCSK9. The sample concentrations 
have been obtained by generating a four-parameter logistic curve-fit. The minimum detectable PCSK9 
concentration was 0.219 ng/mL. Intra- and inter-assay CVs were 3.8% and 5.8%, respectively. 
PCSK9 distribution within plasma lipoproteins was analyzed by FPLC in plasma samples from 6 
homozygotes and 6 heterozygotes carriers of LCAT mutations, 2 homozygotes and 2 heterozygotes 
carriers of ABCA1 mutations, 2 homozygotes and 2 heterozygotes carriers of apoA-I mutations, and 6 
controls using a Superose 6 HR10/30 column (GE Healthcare, UK) [25]. 350 µL of plasma were applied 
to the column, 1.2 ml-fractions were collected; total cholesterol, phospholipid, and PCSK9 concentrations 
were determined by enzymatic techniques. 
 
2.3. Generation of human PCSK9 expression constructs and retroviral infection of HepG2 cells 
To characterize the elution profile of lipoprotein-free PCSK9, the medium from HepG2 cells stably 
overexpressing PCSK9 was analyzed. The retroviral expression plasmid encoding PCSK9-FLAG tag was 
constructed using the pBM-IRES-PURO plasmid. Human PCSK9-FLAG tag cDNA was kindly provided 
by Prof. P. Tarugi (University of Modena) and subcloned into retroviral expression plasmid by blunt-end 
ligation. Retroviral infections of HepG2 were performed as previously described [26, 27]. A polyclonal 
population of HepG2 control and PCSK9 overexpressing cells have been then selected with 10µg/ml of 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
5 
 
puromycin. 
 
2.4. Statistical analyses 
Results are presented as meanSD or as medians and interquartile range, as indicated. The trends in 
plasma lipid/lipoprotein and PCSK9 levels across genotypes were assessed by Spearman correlation. 
Univariable associations between PCSK9 and all plasma lipid/lipoprotein levels were investigated by 
Spearman correlation. Multivariable analyses, adjusted for age, gender,blood lipids, and statin use were 
performed by covariance analysis. To determine if the associations of PCSK9 with plasma variables 
differed between controls and carriers, the appropriate interaction terms were included in the statistical 
models. Variables with skewed distributions were log-transformed before analysis. P values < 0.05 were 
considered as statistically significant. All analyses were performed by using the SAS Software version 9.4 
(SAS Inc, Cary, NC). 
 
3. Results 
3.1. Characteristics of the subjects 
Three different groups of carriers of genetic HDL disorders participated in the study. The first and 
largest group included carriers of LCAT deficiency (19 homozygotes and 60 heterozygotes) [17]; 35 non 
affected family members acted as controls. As previously reported, carriers of LCAT gene mutations have 
significantly reduced HDL-C, apoA-I, apoA-II, LpA-I, LpA-I:A-II levels, and LCAT mass and activity 
with a gene-dose dependent effect. Plasma LDL-C and apoB levels were also significantly reduced, while 
triglyceride levels and preβ-HDL were significantly increased (Table 1). Two of the 19 homozygous and 
7 of the 60 heterozygous carriers were taking lipid-lowering drugs (statins, n=6; fibrates, n=2; ezetimibe, 
n=1); none of the control subjects was taking drugs.  
Two smaller groups included carriers of mutations in the ABCA1 gene (2 homozygotes and 2 
heterozygotes) [18], or in the APOAI gene (2 homozygotes and 4 heterozygotes) [19, 20]. None of the 
subjects was taking lipid-lowering drugs. The characteristics of these carriers are reported in Table 2. 
 
3.2. Plasma PCSK9 levels in carriers of genetic HDL defects 
We first measured total plasma PCSK9 levels in carriers of LCAT gene mutations and family controls. 
Plasma PCSK9 levels in controls were within the reported normal range (198.9±81.1 ng/mL) [28]. 
Carriers of LCAT gene mutations showed plasma PCSK9 levels comparable to controls (heterozygotes, 
180.3 ng/mL (127.6,251.5) and homozygotes, 159.4 ng/mL (124.9,243.3); P for trend adjusted =0.42) 
(Figure 1). Notably, upon correction for age, gender, all the lipid parameters reported in Table 1, and 
statin use, the P for trend value did not vary (P=0.33). 
As previously reported in different observational studies [28-30], a direct association between plasma 
PCSK9 concentration, age, total cholesterol, LDL-C, non-HDL cholesterol, and apoB levels was 
observed in the entire cohort of subjects (Table 3). In addition, significant positive correlations between 
plasma PCSK9 levels and unesterified cholesterol, phospholipid, and LpA-I levels and a significant 
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negative correlation with pre-HDL were found (Table 3). Interestingly, when carriers of LCAT 
deficiency and controls were analyzed separately, a significant positive correlation between PCSK9 and 
HDL-C levels was detected only in controls (P for interaction=0.017, Table 3). A positive association 
was also detected between PCSK9 and LpA-I levels and LCAT activity only in controls (P for 
interaction=0.052 and 0.032, respectively, Table 3).  
The measurement of plasma PCSK9 levels in carriers of mutations in the ABCA1 and APOAI genes 
confirmed the observation that the severe HDL defect was associated with plasma PCSK9 levels similar 
to those of controls (Figure 1). 
 
3.3. PCSK9 distribution within plasma lipoproteins in carriers of genetic HDL disorders 
We next determined the distribution of PCSK9 within plasma lipoproteins by FPLC analysis. 
Lipoprotein profiles of 4 control subjects, with different plasma lipids, are reported in Figure 2. As 
expected, and independently from the lipid profile, the majority of cholesterol was found in LDL 
(fractions 14-18), and a lower amount in HDL (fractions 19-25); phospholipids were almost equally 
distributed between LDL and HDL. In all the subjects, PCSK9 peaked in a region between LDL and HDL 
(Figure 2). Interestingly, the elution peak of cell derived PCSK9 was superimposable to that of controls 
(Figure 2 - Control 1). 
The lipoprotein profile of homozygous carriers of LCAT deficiency remarkably differed from that of 
controls, with a dramatic reduction of HDL, almost no detectable, and a prevalence of large, 
phospholipid-enriched LDL-VLDL particles (Figure 3). Notably, the lipoprotein distribution of PCSK9 in 
LCAT deficient carriers was superimposable to that of controls, despite the severe HDL deficiency 
(Figure 2 and 3), and indeed only minimally overlapped the cholesterol profile (Figure 3). The lipoprotein 
profiles of carriers of ABCA1 and apoA-I mutations also revealed the complete defect of lipids in the 
HDL region, and confirmed a PCSK9 lipoprotein distribution similar to that of controls (Figure 2 and 3). 
 
4. Discussion and conclusion 
The present study shows, for the first time, that PCSK9 levels are within the normal range in carriers 
of genetic HDL disorders, and that the lipoprotein distribution of the circulating PCSK9 is also 
maintained despite the severe HDL defect.  
Plasma concentrations of PCSK9 vary over approximately a 100-fold range (33–2988 ng/ml) in the 
population [28], and PCSK9 half-life time in circulation is very short, approximately 5-15 minutes [3, 
31]. The clearance of PCSK9, at least in mice, occurs in two phases; the first, rapid and dependent upon 
LDLR, while the second largely independent from the LDLR [31]. The degradation of LDLR in mouse 
liver occurs at 30 min post-injection of recombinant PCSK9, thus with a significantly slower kinetic than 
the clearance of PCSK9 [3, 31]. These data indicate that the mechanisms behind PCSK9-driven LDLR 
degradation are still largely unknown. PCSK9 is also able to self-associate in order to form dimers and 
trimers, which showed an improved LDLR degrading activity compared to monomeric PCSK9 [14]. HDL 
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partially inhibit the PCSK9 self-association and thus may reduce the efficacy of PCSK9 to degrade the 
LDLR [14]. 
Several observational and clinical trials have documented the correlation of PCSK9 plasma levels with 
several metabolic parameters including HDL-C [28-30]. These studies were performed starting from the 
assumption that PCSK9 was present in a free-form in plasma. However, an important breakthrough in this 
field was the discovery that PCSK9 is detected in different lipoprotein particles including LDL [8, 14], 
Lp(a) [9], and HDL [14, 15]. 
In the present study, we took advantage of the availability of a large series of Italian carriers of genetic 
HDL defects to study the impact of partial or complete HDL deficiency on PCSK9 metabolism. Carriers 
of genetic HDL disorders are characterized by a significant reduction in plasma HDL levels, associated 
with profound changes in HDL subclasses [32, 33], and thus represent a unique tool to study PCSK9 
distribution within plasma lipoproteins. The results of this study show that in spite of the dramatic 
changes in lipoprotein profile, total plasma levels of PCSK9 are within the normal range in carriers of 
HDL deficiency, suggesting that the HDL defect does not alter PCSK9 homeostasis. The analysis of 
PCSK9 lipoprotein distribution by FPLC confirmed the observation that in control plasma PCSK9 is 
detected in fractions corresponding to LDL and HDL, as previously reported [15], and independently 
from plasma lipids and the presence or not of Lp(a). Surprisingly, the same lipoprotein distribution of 
PCSK9 was detected in plasma from carriers of different genetic HDL defects. Moreover, the elution 
profile of cell derived, lipoprotein-free PCSK9 was superimposable to the PCSK9 profile observed in 
controls and carriers, supporting the concept that the majority of plasma PCSK9 is likely in a lipoprotein-
free fraction, as previously reported [8, 9, 34]. 
Interestingly, when carriers and controls were analyzed separately, a positive correlation between 
PCSK9 and HDL-C levels was observed in controls but not in carriers  Moreover, again only in controls, 
PCSK9 significantly and positively correlated with LpA-I levels and LCAT activity, and negatively with 
pre-HDL, thus suggesting that mature, cholesteryl esters enriched, apoA-I-containing HDL particles 
could be involved in PCSK9 binding. Notably, these specific HDL subclasses are very reduced or even 
absent in carriers of LCAT deficiency [17, 35], which should lead to reduced PCSK9 levels if they were 
involved in PCSK9 transport in plasma.  
LDL contribute to transport of PCSK9 in plasma [6, 8], and indeed in our entire cohort we confirmed 
a positive association of PCSK9 to LDL-C and apoB as previously reported [30, 36-38]. In support to the 
role of LDL in PCSK9 transport, using an approach similar to the one used in the present study it has 
been shown that carriers of familial hypobetalipoproteinemia due to mutations in apoB (FHBL1) or in 
ANGPTL3 (FHBL2), characterized by very low circulating LDL, have significantly reduced plasma 
PCSK9 levels [34, 36]. Interestingly, Lambert et al have shown that in carriers of FHBL1 plasma PCSK9 
levels do not correlate with non-HDL cholesterol, in contrast to what observed in control subjects [36]. 
Lp(a) has also been shown to bind PCSK9, specifically in subjects with high levels of Lp(a) (39 to 320 
mg/dl) [9]. In our cohort of subjects Lp(a) does not seem to play a major role in PCSK9 transport, since 
the cohort includes many subjects with undetectable Lp(a) levels. Moreover, PCSK9 lipoprotein 
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distribution was not affected by Lp(a) levels in control subjects, as shown in Figure 2. Finally, we could 
detect a weak association between PCSK9 and Lp(a) levels only in controls and not in carriers, thus 
excluding that in genetic HDL defects the binding of PCSK9 to Lp(a) may play an important role in 
PCSK9 homeostasis.  
In conclusion, the present study demonstrates that conditions characterized by genetically determined 
very low HDL levels are associated with normal PCSK9 plasma concentrations and lipoprotein 
distribution, thus suggesting that HDL may not be involved in PCSK9 transport in plasma.  
 
Conflict of interest 
The authors declare no conflict of interest. 
 
Acknowledgements 
This work was supported in part by Fondazione Cariplo (2015-0552 to M.R.), by Telethon Italy 
(GGP14125 to L.C.), and by University of Padova, Department of Pharmaceutical and Pharmacological 
Sciences (grant PRID to N.F.). 
 
References 
[1]  N. Ferri, S. Marchiano, G. Tibolla, R. Baetta, A. Dhyani, M. Ruscica, P. Uboldi, A.L. Catapano, A. 
Corsini, PCSK9 knock-out mice are protected from neointimal formation in response to 
perivascular carotid collar placement, Atherosclerosis, 253 (2016) 214-224. 
[2]  N. Ferri, G. Tibolla, A. Pirillo, F. Cipollone, A. Mezzetti, S. Pacia, A. Corsini, A.L. Catapano, 
Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells 
reduces macrophages LDLR levels, Atherosclerosis, 220 (2012) 381-386. 
[3]  R.J. Schmidt, T.P. Beyer, W.R. Bensch, Y.W. Qian, A. Lin, M. Kowala, W.E. Alborn, R.J. Konrad, 
G. Cao, Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and 
extrahepatic low-density lipoprotein receptors in vivo, Biochem Biophys Res Commun, 370 (2008) 
634-640. 
[4]  N.G. Seidah, A. Prat, The biology and therapeutic targeting of the proprotein convertases, Nature 
reviews. Drug discovery, 11 (2012) 367-383. 
[5]  B. Han, P.I. Eacho, M.D. Knierman, J.S. Troutt, R.J. Konrad, X. Yu, K.M. Schroeder, Isolation and 
characterization of the circulating truncated form of PCSK9, J Lipid Res, 55 (2014) 1505-1514. 
[6]  H. Tavori, I. Giunzioni, M.F. Linton, S. Fazio, Loss of plasma proprotein convertase 
subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis, Circ Res, 113 (2013) 1290-1295. 
[7]  M. Hori, M. Ishihara, Y. Yuasa, H. Makino, K. Yanagi, T. Tamanaha, I. Kishimoto, T. Kujiraoka, 
H. Hattori, M. Harada-Shiba, Removal of plasma mature and furin-cleaved proprotein convertase 
subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: 
development and application of a new assay for PCSK9, The Journal of clinical endocrinology and 
metabolism, 100 (2015) E41-49. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
9 
 
[8]  T. Kosenko, M. Golder, G. Leblond, W. Weng, T.A. Lagace, Low density lipoprotein binds to 
proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-
mediated low density lipoprotein receptor degradation, J Biol Chem, 288 (2013) 8279-8288. 
[9]  H. Tavori, D.C. Christian, J. Minnier, D. Plubell, M.D. Shapiro, C. Yeang, I. Giunzioni, M. Croyal, 
P.B. Duell, G. Lambert, S. Tsimikas, S. Fazio, PCSK9 Association With Lipoprotein(a), Circ Res, 
(2016). 
[10]  N.R. Desai, P. Kohli, R.P. Giugliano, M.L. O'Donoghue, R. Somaratne, J. Zhou, E.B. Hoffman, F. 
Huang, W.J. Rogers, S.M. Wasserman, R. Scott, M.S. Sabatine, AMG145, a monoclonal antibody 
against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in 
hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment 
with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined 
with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial, 
Circulation, 128 (2013) 962-969. 
[11] D. Gaudet, D.J. Kereiakes, J.M. McKenney, E.M. Roth, C. Hanotin, D. Gipe, Y. Du, A.C. Ferrand, 
H.N. Ginsberg, E.A. Stein, Effect of alirocumab, a monoclonal proprotein convertase 
subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every 
two weeks dosing from phase 2 trials), Am J Cardiol, 114 (2014) 711-715. 
[12]  J.B. Edmiston, N. Brooks, H. Tavori, J. Minnier, B. Duell, J.Q. Purnell, T. Kaufman, C. Wojcik, S. 
Voros, S. Fazio, M.D. Shapiro, Discordant response of low density lipoprotein cholesterol and 
lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 
9, Journal of clinical lipidology, (2017). 
[13]  N. Ferri, A. Corsini, C. Macchi, P. Magni, M. Ruscica, Proprotein convertase subtilisin kexin type 
9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence, 
Translational research : the journal of laboratory and clinical medicine, 173 (2016) 19-29. 
[14] D. Fan, P.G. Yancey, S. Qiu, L. Ding, E.J. Weeber, M.F. Linton, S. Fazio, Self-association of human 
PCSK9 correlates with its LDLR-degrading activity, Biochemistry, 47 (2008) 1631-1639. 
[15] Y. Luo, L. Warren, D. Xia, H. Jensen, T. Sand, S. Petras, W. Qin, K.S. Miller, J. Hawkins, Function 
and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice, J Lipid 
Res, 50 (2009) 1581-1588. 
[16]  H. Tavori, S. Rashid, S. Fazio, On the function and homeostasis of PCSK9: reciprocal interaction 
with LDLR and additional lipid effects, Atherosclerosis, 238 (2015) 264-270. 
[17]  L. Calabresi, L. Pisciotta, A. Costantin, I. Frigerio, I. Eberini, P. Alessandrini, M. Arca, G.B. Bon, 
G. Boscutti, G. Busnach, G. Frasca, L. Gesualdo, M. Gigante, G. Lupattelli, A. Montali, S. 
Pizzolitto, I. Rabbone, M. Rolleri, G. Ruotolo, T. Sampietro, A. Sessa, G. Vaudo, A. Cantafora, F. 
Veglia, S. Calandra, S. Bertolini, G. Franceschini, The molecular basis of lecithin:cholesterol 
acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical 
findings in 13 unrelated Italian families, Arterioscler Thromb Vasc Biol, 25 (2005) 1972-1978. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
10 
 
[18]  L. Pisciotta, L. Bocchi, C. Candini, R. Sallo, I. Zanotti, T. Fasano, A. Chakrapani, T. Bates, R. 
Bonardi, A. Cantafora, S. Ball, G. Watts, F. Bernini, S. Calandra, S. Bertolini, Severe HDL 
deficiency due to novel defects in the ABCA1 transporter, Journal of internal medicine, 265 (2009) 
359-372. 
[19]  L. Pisciotta, R. Miccoli, A. Cantafora, L. Calabresi, P. Tarugi, P. Alessandrini, G. Bittolo Bon, G. 
Franceschini, C. Cortese, S. Calandra, S. Bertolini, Recurrent mutations of the apolipoprotein A-I 
gene in three kindreds with severe HDL deficiency, Atherosclerosis, 167 (2003) 335-345. 
[20]  L. Pisciotta, C. Vitali, E. Favari, P. Fossa, M.P. Adorni, D. Leone, N. Artom, R. Fresa, L. 
Calabresi, S. Calandra, S. Bertolini, A complex phenotype in a child with familial HDL deficiency 
due to a novel frameshift mutation in APOA1 gene (apoA-IGuastalla), Journal of clinical 
lipidology, 9 (2015) 837-846. 
[21]  T. Fasano, P. Zanoni, C. Rabacchi, L. Pisciotta, E. Favari, M.P. Adorni, P.B. Deegan, A. Park, T. 
Hlaing, M.D. Feher, B. Jones, A.S. Uzak, F. Kardas, A. Dardis, A. Sechi, B. Bembi, P. Minuz, S. 
Bertolini, F. Bernini, S. Calandra, Novel mutations of ABCA1 transporter in patients with Tangier 
disease and familial HDL deficiency, Molecular genetics and metabolism, 107 (2012) 534-541. 
[22]  S. Altilia, L. Pisciotta, R. Garuti, P. Tarugi, A. Cantafora, L. Calabresi, J. Tagliabue, S. Maccari, F. 
Bernini, I. Zanotti, C. Vergani, S. Bertolini, S. Calandra, Abnormal splicing of ABCA1 pre-mRNA 
in Tangier disease due to a IVS2 +5G>C mutation in ABCA1 gene, J Lipid Res, 44 (2003) 254-
264. 
[23]  L. Pisciotta, I. Hamilton-Craig, P. Tarugi, A. Bellocchio, T. Fasano, P. Alessandrini, G.B. Bon, D. 
Siepi, E. Mannarino, L. Cattin, M. Averna, A.B. Cefalu, A. Cantafora, S. Calandra, S. Bertolini, 
Familial HDL deficiency due to ABCA1 gene mutations with or without other genetic lipoprotein 
disorders, Atherosclerosis, 172 (2004) 309-320. 
[24]  M. Ruscica, N. Ferri, C. Macchi, M. Meroni, C. Lanti, C. Ricci, M. Maggioni, A.L. Fracanzani, S. 
Badiali, S. Fargion, P. Magni, L. Valenti, P. Dongiovanni, Liver fat accumulation is associated 
with circulating PCSK9, Annals of medicine, 48 (2016) 384-391. 
[25] S. Simonelli, C. Tinti, L. Salvini, L. Tinti, A. Ossoli, C. Vitali, V. Sousa, G. Orsini, M.L. Nolli, G. 
Franceschini, L. Calabresi, Recombinant human LCAT normalizes plasma lipoprotein profile in 
LCAT deficiency, Biologicals : journal of the International Association of Biological 
Standardization, 41 (2013) 446-449. 
[26]  M. Ruscica, C. Ricci, C. Macchi, P. Magni, R. Cristofani, J. Liu, A. Corsini, N. Ferri, Suppressor 
of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 
(PCSK9) Expression in Hepatic HepG2 Cell Line, J Biol Chem, 291 (2016) 3508-3519. 
[27]  C. Ricci, M. Ruscica, M. Camera, L. Rossetti, C. Macchi, A. Colciago, I. Zanotti, M.G. Lupo, M.P. 
Adorni, A.F.G. Cicero, F. Fogacci, A. Corsini, N. Ferri, PCSK9 induces a pro-inflammatory 
response in macrophages, Scientific reports, 8 (2018) 2267. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
11 
 
[28]  S.G. Lakoski, T.A. Lagace, J.C. Cohen, J.D. Horton, H.H. Hobbs, Genetic and metabolic 
determinants of plasma PCSK9 levels, The Journal of clinical endocrinology and metabolism, 94 
(2009) 2537-2543. 
[29]  G. Paradis, M. Lambert, J. O'Loughlin, C. Lavallee, J. Aubin, P. Berthiaume, M. Ledoux, E.E. 
Delvin, E. Levy, J.A. Hanley, The Quebec Child and Adolescent Health and Social Survey: design 
and methods of a cardiovascular risk factor survey for youth, The Canadian journal of cardiology, 
19 (2003) 523-531. 
[30]  A. Baass, G. Dubuc, M. Tremblay, E.E. Delvin, J. O'Loughlin, E. Levy, J. Davignon, M. Lambert, 
Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based 
sample of children and adolescents, Clin Chem, 55 (2009) 1637-1645. 
[31]  A. Grefhorst, M.C. McNutt, T.A. Lagace, J.D. Horton, Plasma PCSK9 preferentially reduces liver 
LDL receptors in mice, J Lipid Res, 49 (2008) 1303-1311. 
[32] F. Oldoni, R.J. Sinke, J.A. Kuivenhoven, Mendelian disorders of high-density lipoprotein 
metabolism, Circ Res, 114 (2014) 124-142. 
[33]  L. Calabresi, M. Gomaraschi, S. Simonelli, F. Bernini, G. Franceschini, HDL and atherosclerosis: 
Insights from inherited HDL disorders, Biochimica et biophysica acta, 1851 (2015) 13-18. 
[34]  S. Fazio, J. Minnier, M.D. Shapiro, S. Tsimikas, P. Tarugi, M.R. Averna, M. Arca, H. Tavori, 
Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins, The Journal 
of clinical endocrinology and metabolism, 102 (2017) 3340-3348. 
[35]  B.F. Asztalos, E.J. Schaefer, K.V. Horvath, S. Yamashita, M. Miller, G. Franceschini, L. Calabresi, 
Role of LCAT in HDL remodeling: investigation of LCAT deficiency states, J Lipid Res, 48 
(2007) 592-599. 
[36]  G. Lambert, F. Petrides, M. Chatelais, D.J. Blom, B. Choque, F. Tabet, G. Wong, K.A. Rye, A.J. 
Hooper, J.R. Burnett, P.J. Barter, A.D. Marais, Elevated plasma PCSK9 level is equally detrimental 
for patients with nonfamilial hypercholesterolemia and heterozygous familial 
hypercholesterolemia, irrespective of low-density lipoprotein receptor defects, J Am Coll Cardiol, 
63 (2014) 2365-2373. 
[37]  M. Ruscica, N. Ferri, F. Fogacci, M. Rosticci, M. Botta, S. Marchiano, P. Magni, S. D'Addato, M. 
Giovannini, C. Borghi, A.F.G. Cicero, G. Brisighella Heart Study, Circulating Levels of Proprotein 
Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data 
From the Brisighella Heart Study, Journal of the American Heart Association, 6 (2017). 
[38]  G. Welder, I. Zineh, M.A. Pacanowski, J.S. Troutt, G. Cao, R.J. Konrad, High-dose atorvastatin 
causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL 
cholesterol, J Lipid Res, 51 (2010) 2714-2721. 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
12 
 
Table 1 
Demographic and lipid/lipoprotein profile of carriers of LCAT deficiency 
 
 Carriers of LCAT deficiency  P trend 
 Controls HEZ HOZ  
N 35 60 19  
Sex (m/f) 13/22 38/22 16/3 0.0004 
Age (years) 45.1 ± 22.3 47.7 ± 21.3 40.4 ± 18.2 0.52 
Total Cholesterol (mg/dL) 190.4 ± 41.0 166.5 ± 42.9 154.2 ± 84.7 0.002 
Unesterified Cholesterol (mg/dL) 52.1 ± 12.3 51.3 ± 13.3 117.0 ± 72.4 <0.0001 
LDL-Cholesterol (mg/dL) 111.2 ± 33.0 97.1 ± 39.4 92.1 ± 62.8 0.01 
HDL-Cholesterol (mg/dL) 59.6 ± 13.7 42.2 ± 16.2 10.6 ± 7.1 <0.0001 
Non HDL-Cholesterol (mg/dL) 132.6 ± 39.5 124.2 ± 45.4 143.5 ± 86.4 0.66 
Triglycerides (mg/dL) 76.0 (58,108) 110.0 (80,154.5) 180.0 (114,387) <0.0001 
Phospholipids (mg/dL) 205.3 ± 42.7 205.2 ± 65.5 268.6 ± 122.7 0.01 
Apolipoprotein A-I (mg/dL) 128.9 ± 25.0 106.5 ± 26.6 48.4 ± 20.6 <0.0001 
Apolipoprotein A-II (mg/dL) 31.6 ± 6.4 30.0 ± 5.8 9.1 ± 5.7 <0.0001 
Apolipoprotein B (mg/dL) 87.8 ± 24.1 91.8 ± 27.3 67.0 ± 47.1 0.12 
Lp(a) (mg/dL) 12.8 ± 17.0 7.6 ± 10.7 3.6 ± 4.0 <.0001 
LpA-I (mg/dL) 59.0 ± 15.9 44.6 ± 13.9 28.3 ± 15.2 <0.0001 
LpA-I:A-II (mg/dL) 69.8 ± 20.6 61.4 ± 22.8 19.0 ± 16.8 <0.0001 
preβ-HDL (% of apoA-I) 14.1 ± 4.6 16.8 ± 6.4 35.7 ± 16.0 <0.0001 
LCAT concentration (μg/mL) 4.92 ± 0.93 4.05 ± 1.37 1.83 ± 0.95 <0.0001 
LCAT activity (nmol/mL/h) 38.5 ± 12.5 24.5 ± 12.7 nd <0.0001 
Data are reported as mean±SD or median (interquartile range). nd=not detectable   
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Table 2 
Demographic and lipid/lipoprotein profile of carriers of ABCA1 and ApoA-I mutations 
 
 ABCA1 mutations ApoA-I mutations 
 HEZ HOZ  HEZ HOZ 
n 2 2 4 2 
Sex (m/f) 1/1 1/1 2/2 2/0 
Age (years) 55.0 ± 1.4 41.0 ± 21.2 52.8 ± 3.2 34.5 ± 3.5 
Total Cholesterol (mg/dL) 159.5 ± 3.5 117.5 ± 103.9 153.3 ± 21.0  126.0 ± 91.9 
LDL-Cholesterol (mg/dL) 85.5 ± 24.7 79.5 ± 98.3 100.3 ± 15.0  84.0 ± 84.9 
HDL-Cholesterol (mg/dL) 29.5 ± 16.3 2.5 ± 2.1 26.8 ± 17.1  11.5 ± 2.1 
non HDL-Cholesterol (mg/dL) 130.0 ± 12.7 115.0 ± 101.8 126.5 ± 10.1 114.5 ± 94.0 
Triglycerides (mg/dL) 222.5 ± 187.4 177.5 ± 20.5 131.0 ± 81.3 154.5 ± 46.0 
Apolipoprotein A-I (mg/dL) 84.0 ± 17.0 10.5 ± 12.0 70.5 ± 31.8  nd 
Apolipoprotein B (mg/dL) 97.0 ± 12.7 113.0 ± 73.5 91.5 ± 9.6 75.5 ± 30.4 
Lp(a) (mg/dL) 61.0 ± 82.0 39.0 ± 53.7 16.5 ± 21.3  4.5 ± 4.9 
Data are reported as mean±SD. nd=not detectable. 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
14 
 
Table 3 
Variables associated with circulating PCSK9 levels in the studied population (LCAT deficient carriers 
and controls)  
 
 PCSK9 (ng/mL)  
 
Entire cohort 
(n=114) 
Carriers  
(n=79) 
Controls  
(n=35) 
P 
Interaction 
 R P R P R P  
Age (y) 0.19 0.047 0.08 0.530 0.17 0.370  
Total Cholesterol (mg/dL) 0.24 0.011 0.20 0.071 0.29 0.090 0.793 
Unesterified Cholesterol (mg/dL) 0.23 0.013 0.22 0.049 0.35 0.044 0.304 
LDL-Cholesterol (mg/dL) 0.24 0.011 0.21 0.057 0.25 0.150 0.855 
HDL-Cholesterol (mg/dL) 0.11 0.246 -0.04 0.733 0.54 0.001 0.017 
Non-HDL Cholesterol (mg/dL) 0.19 0.047 0.20 0.07 0.16 0.36 0.34 
Triglycerides (mg/dL) 0.02 0.856 0.14 0.224 -0.06 0.729 0.077 
Phospholipids (mg/dL) 0.20 0.037 0.24 0.034 0.14 0.440 0.293 
Lp(a) (mg/dL) 0.18 0.069 0.09 0.416 0.32 0.080 0.546 
Apolipoprotein B (mg/dL) 0.24 0.010 0.26 0.024 0.21 0.237 0.972 
Apolipoprotein A-I (mg/dL) 0.05 0.599 -0.01 0.954 0.17 0.324 0.585 
Apolipoprotein A-II (mg/dL) -0.03 0.765 0.01 0.941 -0.27 0.258 0.010 
LpA-I (mg/dL) 0.23 0.016 0.11 0.322 0.50 0.002 0.052 
LpA-I:A-II (mg/dL) -0.04 0.669 -0.06 0.611 -0.02 0.905 0.433 
preβ-HDL (% of apoA-I) -0.21 0.027 -0.15 0.204 -0.31 0.074 0.553 
LCAT mass (μg/mL) 0.07 0.448 0.03 0.805 0.07 0.702 0.737 
LCAT activity (nmol/mL/h) 0.05 0.588 -0.14 0.233 0.46 0.007 0.032 
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Figure 1 
 
 
 
Fig. 1. Plasma PCSK9 levels (ng/mL; median and interquartile range) were measured by ELISA in 
carriers of LCAT, ABCA1, and apoA-I gene mutations and in non-affected family members (Controls). 
Empty circles are the controls (n=35); empty diamonds are carriers of one mutation in the LCAT gene 
(n=60); black diamonds are carriers of one mutation in the ABCA1 gene (n=2); gray diamonds are carriers 
of one mutation in the APOAI gene (n=4); empty squares are carriers of two mutations in the LCAT gene 
(n=19); black squares are carriers of two mutations in the ABCA1 gene (n=2); gray squares are carriers of 
two mutations in the APOAI gene (n=2). 
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Figure 2 
 
 
 
 
Fig. 2. PCSK9 distribution within plasma lipoproteins in control subjects. FPLC fractions from control 
plasma were analyzed for total cholesterol (TC) and PCSK9. Profiles of four representative controls 
subjects, and their plasma lipids, are reported. Medium released from HepG2 cells overexpressing PCSK9 
(HepG2PCSK9) was fractionated by FPLC (upper left panel, dotted line). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
17 
 
 
Figure 3 
 
 
 
Fig. 3. Lipoprotein profile of carriers of LCAT, ABCA1 and apoA-I gene mutations. FPLC fractions from 
plasma from homozygous carriers of LCAT, ABCA1 and apoA-I gene mutations were analyzed for total 
cholesterol (TC) and PCSK9. Profiles of three representative homozygous carriers, and their plasma 
lipids, are reported. 
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Highlights 
 PCSK9 circulates partially associated to plasma lipoproteins 
 Carriers of genetic HDL defects have significantly reduced plasma HDL levels 
 Genetic HDL defects represent a unique tool to study PCSK9 distribution within lipoproteins 
 Carriers of genetic HDL defects  have normal PCSK9 plasma concentrations 
 HDL particles may not contribute to PCSK9 transport in plasma 
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